Literature DB >> 28882455

Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma.

Omar Abdel-Rahman1.   

Abstract

BACKGROUND: This study seeks to validate the discriminating value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for Hepatocellular carcinoma (HCC) amongst patients registered within the surveillance, epidemiology and end results (SEER) database.
METHODS: Through SEER*Stat program, SEER database (2010-2013) was queried and 8th AJCC stage groups were reconstructed. Overall and cancer-specific survival analyses according to both 7th and 8th editions were conducted through Kaplan-Meier analysis/log-rank testing and multivariate analysis was conducted through a Cox proportional model.
RESULTS: For overall and cancer-specific survival assessment according to the 8th edition, P values for pair wise comparisons among different stages were significant (<0.001) in all comparisons except for stage IB vs. II/stage IIIB vs. stage IVA. A modified AJCC 8th staging system was suggested through collapsing stages IB/II into one stage and stages IIIB/IVA into one stage. Overall and cancer-specific survivals were compared according to this modified system and pair wise P value was significant in all comparisons (P < 0.001).
CONCLUSION: There is a minimal improvement in discriminating value for the 8th edition compared to the 7th edition; however, notable overlap in outcomes is still observed between stages IB/II and IIIB/IVA. A modified AJCC 8th system collapsing these overlapping stages may be more clinically relevant.
Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28882455     DOI: 10.1016/j.hpb.2017.08.017

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  12 in total

1.  The benefit of curative liver resection with a selective bile duct preserving approach for hepatocellular carcinoma with macroscopic bile duct tumor thrombus.

Authors:  Anon Chotirosniramit; Akkaphod Liwattanakun; Sunhawit Junrungsee; Wasana Ko-Iam; Trichak Sandhu; Worakitti Lapisatepun
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

2.  Population-based assessment of the national comprehensive cancer network recommendations for baseline imaging of hepatocellular carcinoma.

Authors:  Omar Abdel-Rahman; Winson Y Cheung
Journal:  Med Oncol       Date:  2019-02-01       Impact factor: 3.064

3.  Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.

Authors:  Li-Ju Chen; Yun-Jau Chang; Yao-Jen Chang
Journal:  Oncologist       Date:  2020-10-03

4.  Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma.

Authors:  Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Seung Woon Paik; Moon Suk Choi; Hye-Seung Kim; Insuk Sohn; Heerim Nam
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 5.  The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma.

Authors:  Omar Abdel-Rahman; Winson Y Cheung
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-07

6.  Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study.

Authors:  Zhenhua Lu; Zhen Sun; Chengyu Liu; Xiaolei Shi; Rui Li; Weiwei Shao; Yangyang Zheng; Yao Li; Jinghai Song
Journal:  BMC Cancer       Date:  2021-06-29       Impact factor: 4.430

7.  Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.

Authors:  Omar Abdel-Rahman
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-17       Impact factor: 4.322

Review 8.  Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies.

Authors:  Qi Zhang; Yu Lou; Xue-Li Bai; Ting-Bo Liang
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

9.  Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma.

Authors:  Xueping Wang; Minjie Mao; Zhonglian He; Lin Zhang; Huilan Li; Jianhua Lin; Yi He; Shuqin Dai; Wanming Hu; Wanli Liu
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

10.  FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Yan Wang; Mengjing Sun; Jibin Liu; Ying Liu; Chunyi Jiang; Huijun Zhu; Wei Wang; Yao Wang
Journal:  Oncol Lett       Date:  2019-12-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.